earnings
confidence high
sentiment positive
materiality 0.75
Paysign Q3 revenue $21.6M (+41.6% YoY); raises full-year 2025 guidance
Paysign, Inc.
2025-Q3 EPS
reported $0.10
vs consensus $0.02
▲ beat
(+390.2%)
- Q3 2025 revenue $21.6M (+41.6% YoY); net income $2.22M (+54.2% YoY); diluted EPS $0.04 vs $0.03 YoY.
- Adjusted EBITDA $5.04M (23.3% margin), up 78.1% YoY; pharma patient affordability revenue surged 141.9% to $7.92M.
- Plasma revenue grew 12.4% to $12.86M; exited with 595 plasma centers (down 12 QoQ) and 105 active pharma programs (up 8 QoQ).
- Raises FY2025 guidance: revenue $80.5M–$81.5M (38.7% YoY midpoint), net income $7.0M–$8.0M, Adjusted EBITDA $19.0M–$20.0M.
- Ended quarter with $7.53M unrestricted cash, zero bank debt; opened new 30,000 sq ft customer service center.